Business
US contract sales partnership
Oxford BioDynamics Plc has partnered with MK Commercial Group to expand its US commercial footprint for its EpiSwitch® PSE prostate cancer diagnostic test, initially deploying seven sales professionals with the potential to scale to 35 representatives. This agreement will extend OBD's reach into key metropolitan markets such as New Jersey, Washington DC, Virginia, Georgia, and the Chicago area, enhancing physician-facing commercial engagement without the fixed costs of a fully employed sales force. The partnership aims to accelerate the adoption of EpiSwitch® PSE by leveraging MKCG's experience in scaling diagnostic businesses. Disclaimer*
About this update from Oxford Biodynamics Plc
30 June 2026 Oxford BioDynamics Plc ("OBD" or the "Company" and, together with its subsidiaries, the "Group") Oxford BioDynamics expands US commercial footprint through contract sales partnership with MK Commercial Group • OBD has entered into a commercial services agreement with MK Commercial Group ("MKCG"), a specialist life sciences contract commercialisation organisation, to initially deploy seven field-based sales professionals across the United States, with the ability to scale to up to 35 representatives as commercial demand warrants • The expanded sales force extends OBD's commercial presence into major metropolitan markets, including New Jersey, Washington DC, Virginia, Georgia, and the Chicago metropolitan area, that have not previously had dedicated field coverage • MKCG has an impressive reputation and track record of scaling laboratory diagnostic businesses from early adoption through to public markets • The partnership materially increases OBD's physician-facing commercial reach across the US without the fixed-cost structure of a fully employed sales organisation Oxford, UK - 30 June 2026 - Oxford BioDynamics Plc (AIM: OBD, the Company), the international biotechnology company advancing personalized healthcare through precision clinical diagnostic tests and EpiSwitch® Orion, a cloud-based 3D genomics platform that transforms existing datasets into actionable insights for pharma and biotech partners, announces a partnership with contract sales organisation MK Commercial Group to extend its US commercial presence and drive growth of EpiSwitch® PSE. This agreement builds on OBD's established US commercial strategy of deploying independent field specialists in targeted markets, representing a significant acceleration of this strategy across a broader set of major metropolitan areas. EpiSwitch® PSE is designed to bring greater confidence and precision to the prostate cancer diagnostic pathway. Current and accepted practice in the diagnosis of prostate c...
View stock analysis, news, and events for Oxford Biodynamics Plc